Participant flow

Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer · Source last updated 2019-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Bevacizumab 15 mg/kg IV, every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy

   id

   FG000

   title

   Bevacizumab

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Ineligible: wrong primary

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      type

      Never treated

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         64

      type

      STARTED

   2. achievements

      1. comment

         Eligible and treated patients.

         group Id

         FG000

         num Subjects

         62

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         2

      type

      NOT COMPLETED

   title

   Overall Study

recruitment Details

The study was activated on 4/29/2002 and closed to accrual on 8/25/2004 (suspended from 10/6/2003 to 12/1/2003).

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice